Literature DB >> 21502246

Integrating safety and efficacy evaluation throughout vaccine research and development.

George Curlin1, Sarah Landry, Jessica Bernstein, Richard L Gorman, Barbara Mulach, Charles J Hackett, Stephanie Foster, Sarah E Miers, Patricia Strickler-Dinglasan.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21502246      PMCID: PMC4536579          DOI: 10.1542/peds.2010-1722C

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


× No keyword cloud information.
  4 in total

1.  Mercury levels in premature and low birth weight newborn infants after receipt of thimerosal-containing vaccines.

Authors:  Michael E Pichichero; Angela Gentile; Norberto Giglio; Margarita Martin Alonso; Maria Veronica Fernandez Mentaberri; Grazyna Zareba; Thomas Clarkson; Carlos Gotelli; Mariano Gotelli; Lihan Yan; John Treanor
Journal:  J Pediatr       Date:  2009-06-26       Impact factor: 4.406

2.  Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines.

Authors:  Michael E Pichichero; Angela Gentile; Norberto Giglio; Veronica Umido; Thomas Clarkson; Elsa Cernichiari; Grazyna Zareba; Carlos Gotelli; Mariano Gotelli; Lihan Yan; John Treanor
Journal:  Pediatrics       Date:  2008-02       Impact factor: 7.124

3.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans.

Authors:  Troy D Querec; Rama S Akondy; Eva K Lee; Weiping Cao; Helder I Nakaya; Dirk Teuwen; Ali Pirani; Kim Gernert; Jiusheng Deng; Bruz Marzolf; Kathleen Kennedy; Haiyan Wu; Soumaya Bennouna; Herold Oluoch; Joseph Miller; Ricardo Z Vencio; Mark Mulligan; Alan Aderem; Rafi Ahmed; Bali Pulendran
Journal:  Nat Immunol       Date:  2008-11-23       Impact factor: 25.606

4.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants.

Authors:  Stephanie C Eisenbarth; Oscar R Colegio; William O'Connor; Fayyaz S Sutterwala; Richard A Flavell
Journal:  Nature       Date:  2008-05-21       Impact factor: 49.962

  4 in total
  3 in total

1.  Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.

Authors:  Gajalakshmi Dakshinamoorthy; Ramaswamy Kalyanasundaram
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

2.  The importance of animal models in tuberculosis vaccine development.

Authors:  Armando Acosta; Mohd Nor Norazmi; Rogelio Hernandez-Pando; Nadine Alvarez; Reinier Borrero; Juan F Infante; Maria E Sarmiento
Journal:  Malays J Med Sci       Date:  2011-10

3.  The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Authors:  Robert T Chen; Baevin Carbery; Lisa Mac; Kenneth I Berns; Louisa Chapman; Richard C Condit; Jean-Louis Excler; Marc Gurwith; Michael Hendry; Arifa S Khan; Najwa Khuri-Bulos; Bettina Klug; James S Robertson; Stephen J Seligman; Rebecca Sheets; Anna-Lise Williamson
Journal:  Vaccine       Date:  2014-10-08       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.